Friday, July 8, 2022

Welcome Address
5:30 pm- 5:40 pm

Keynotes Lectures
Session Chair: Kohei Miyazono, The University of Tokyo, Tokyo, Japan
5:40 pm-7:00 pm
Pancreatic cancer is PRIMED to become an immunologic disease
Elizabeth M. Jaffee, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Dissecting pancreatic cancer development with advanced mouse models
Yasuhiro Yamada, The University of Tokyo, Tokyo, Japan

Special Session: Patient and Public Involvement
7:00 pm- 7:30 pm
Pancreatic Cancer Research and PPI
Yoshiyuki Majima, Pancreatic Cancer Action Network, Tokyo, Japan

Welcome Party
7:50 pm- 9:50 pm
Saturday, July 9, 2022

Session 1: Stromal evolution and tumor microenvironment cross-talk and modeling
8:30 am-10:00 am

Dissecting T cell responses in human and mouse pancreatic cancer
**Marina Pasca di Magliano**, University of Michigan, Ann Arbor, Michigan

Understanding the biology of cancer-restraining fibroblasts in pancreatic cancer and its clinical application
**Atushi Enomoto**, Nagoya University Graduate School of Medicine, Nagoya, Japan

Contribution of tumor endothelial cells in tumor progression
**Kyoko Hida**, Hokkaido University, Hokkaido, Japan

Break
10:00 am- 10:20 am

Session 2: Inflammation
10:20 am-11:50 am

Microbial matters in pancreatic cancer: From inception to progression
**Florencia McAllister**, The University of Texas MD Anderson Cancer Center, Houston, Texas

The role of chromatin remodeling regulators in pancreatic cancer
**Akihisa Fukuda**, Kyoto University Graduate School of Medicine, Kyoto, Japan

Shift of immune-inflammatory microenvironment in regulating pancreatic cancer
**Hideaki Ijichi**, The University of Tokyo Hospital, Tokyo, Japan

Lunch and Poster View
11:50 am- 12:50 pm

Poster Presentation
12:50 pm- 2:20 pm
Session 3: Genetics, Kras, p53, and oncogenic signaling
2:20 pm-3:50 pm

Stress-adaptation in cancer: Role of stress granules in pancreatic tumorigenesis
Elda Grabocka, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

The importance of the p53 pathway in pancreatic neuroendocrine tumors
Rieko Ohki, National Cancer Center Research Institute, Tokyo, Japan

A whole-animal approach to identify therapeutic vulnerabilities in pancreatic cancer
Masahiro Sonoshita, Hokkaido University Institute for Genetic Medicine, Hokkaido, Japan

Break
3:50 pm- 4:10 pm

Session 4: Tumor heterogeneity, plasticity, and therapy resistance
4:10 pm-5:40 pm

Post-translational activation of MYC promotes cellular plasticity and aggressive, metastatic pancreatic cancer
Rosalie C. Sears, Oregon Health and Science University, Portland, Oregon

Title to be announced
Toshiro Sato, Keio University School of Medicine, Tokyo, Japan

Elucidation and control of cancer ecosystem using artificial cancer tissue
Keisuke Sekine, National Cancer Center Research Institute, Tokyo, Japan

Meet the Expert Evening
6:00 pm- 7:00 pm

Banquet
7:30 pm- 9:30 pm
Sunday, July 10, 2022

Session 5: Screening and early detection, liquid biopsy, biomarkers, and premalignant lesions
8:30 am-10:00 am

Early detection and cancer interception in pancreatic cancer

**Anirban Maitra**, The University of Texas MD Anderson Cancer Center, Houston, Texas

Increased levels of branched-chain amino acid associated with increased risk of pancreatic cancer in a prospective case-control study in a large cohort

**Ryoko Katagiri**, National Cancer Center Institute for Cancer Control, Tokyo, Japan

Premalignant lesions of the pancreatic cancer

**Toru Furukawa**, Tohoku University Graduate School of Medicine, Miyagi, Japan

Break
10:00 am- 10:20 am

Session 6: Clinical oncology and targeted therapies
10:20 am-11:50 am

Stronger together: Immuno-energizing non-IO drugs in novel combinations

**Nilofer S. Azad**, Johns Hopkins University, Baltimore, Maryland

Recent progress of precision medicine in the treatment of pancreatic cancer

**Masashi Kanai**, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University

Current status and clinical trials in chemotherapy for pancreatic cancer in Japan

**Junji Furuse**, Kanagawa Cancer Center, Tokyo, Japan

Lunch
11:50 am- 12:50 pm
Session 7: Immunotherapy
12:50 pm- 2:20 pm

The role of altered lipid metabolism in pancreatic cancer cachexia

**Stephanie K. Dougan**, Dana-Farber Cancer Institute, Boston, Massachusetts

Inhibitor-induced stromal and metabolic reprogramming enhances pancreatic cancer therapy

**Yasuyuki Kida**, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan

Immune suppression in the tumor microenvironment

**Hiroyoshi Nishikawa**, Nagoya University Graduate School of Medicine, Nagoya, Japan; National Cancer Center, Tokyo, Japan

Break
2:20 pm-2:40 pm

Session 8: Metabolism, antioxidants, and cachexia
2:40 pm- 4:10 pm

The role of altered lipid metabolism in pancreatic cancer cachexia

**Aaron Grossberg**, Oregon Health & Science University, Portland, Oregon

The landscape of systemic metabolic alterations in cancer cachexia

**Masahiro Aoki**, Division of Pathophysiology, Aichi Cancer Center Research Institute

Translational research for clinical trials in human pancreatic cancer

**Atsushi Ochiai**, The Research Institute for Biological Sciences, Tokyo University of Sciences

Closing Remarks
4:10 pm- 4:20 pm